During a live event, Yelena Y. Janjigian, MD, moderated a discussion on how to use PD-L1 CPS status when considering ...

アジレント・テクノロジー株式会社がPD-L1 IHC 22C3 pharmDx「ダコ」の追加承認を取得 HER2陰性の治癒切除不能進行・再発の胃癌患者に対するキイトルーダ(R)（一般名 : ペムブロリズマブ（遺伝子組換え））の投与に際し、PD-L1の発現状況を検査するための体外 ...

Sac-TMT combined with Keytruda significantly improves progression-free survival in PD-L1-positive advanced non-small cell lung cancer. The OptiTROP-Lung05 study is the first phase 3 trial of an ...

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced FDA approval to initiate COMPASSION-37/AK104-311 trial, a global multicenter Phase III trial in gastric cancer evaluating cadonilimab, a ...

Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients with advanced or metastatic solid tumors, ...

Leronlimab treatment is associated with upregulation of PD-L1 in circulating tumor cells and cancer-associated macrophage-like cells Remarkably longer survival was observed in patients treated with ...

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced FDA approval to initiate COMPASSION-37/AK104-311 trial, a global ...

The battle against cancer is witnessing a revolutionary leap forward with PD-1/PD-L1 Inhibitors Market. These groundbreaking treatments are transforming the landscape of cancer care. According to a ...